Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States
Abstract Background:. We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016.
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 March 2016
|
| In: |
Journal of the National Cancer Institute
Year: 2016, Jahrgang: 108, Heft: 7 |
| ISSN: | 1460-2105 |
| DOI: | 10.1093/jnci/djw003 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1093/jnci/djw003 Verlag, Volltext: https://academic.oup.com/jnci/article/108/7/djw003/2412626 
|
| Verfasserangaben: | William V. Padula, Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joelle Guilhot, Francois Guilhot, Rudiger Hehlmann, Francois-Xavier Mahon, Giovanni Martinelli, Jiri Mayer, Martin C. Müller, Dietger Niederwieser, Susanne Saussele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Rena M. Conti |
| Zusammenfassung: | Abstract Background:. We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016. |
|---|---|
| Beschreibung: | Gesehen am 01.02.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1460-2105 |
| DOI: | 10.1093/jnci/djw003 |